News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Argos Therapeutics, Inc. To Present At The Elsevier, Inc. Therapeutic Area Partnerships Meeting


11/13/2013 9:02:39 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

DURHAM, N.C., Nov. 12, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform, today announced that Jeff Abbey, president and chief executive officer, is scheduled to present at the Elsevier Therapeutic Area Partnerships Meeting on November 19 at the Hyatt Regency Boston.

Event:

Elsevier Therapeutic Area Partnerships Meeting



Date:

Tuesday, November 19, 2013



Time:

2:55 PM



Location:

Duxbury Room, 4th Floor


Hyatt Regency Boston


1 Avenue De Lafayette, Boston, MA 02111

Mr. Abbey will present an overview of the clinical development program for the Company's investigational fully personalized immunotherapy targeted to HIV, AGS-004, which has been designated as one of the "Top Projects to Watch" in infectious disease at the meeting.

About the Arcelis Technology Platform

Arcelis is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies.

The Arcelis process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform. Argos' most advanced product candidate, AGS-003, has initiated a pivotal Phase 3 study for the treatment of mRCC, and the Company recently completed enrollment of its Phase 2b study of AGS-004 for the treatment of HIV. For more information about Argos Therapeutics, visit www.argostherapeutics.com.

SOURCE Argos Therapeutics Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES